Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Neuren (ASX:NEU) was the biggest faller in lunchtime trades on Friday after announcing some children were "minimally improved" in phase 2 of a trial treating children with Angelman syndrome.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
No Corporate Spotlight currently available.